M.D. Anderson Cancer Center: Gliosarcoma trials

The registry lists 13 Gliosarcoma studies with M.D. Anderson Cancer Center as lead sponsor. 3 are open to participants now and 3 have results posted.

Phase 1 11Phase 2 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMRecruitingNCT04991870Phase 1
• HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsRecruitingNCT03911388Phase 1
• MSC-DNX-2401 in Treating Patients With Recurrent High-Grade GliomaRecruitingNCT03896568Phase 1
• Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT03174197Phase 1/2Results posted
• Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With GlioblastomaCompletedNCT02661282Phase 1/2Results posted
• Pembrolizumab in Treating Patients With Recurrent GlioblastomaActive, not recruitingNCT02337686Phase 2Results posted
• Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05039281Phase 1/2
• Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent GlioblastomaActive, not recruitingNCT04555577Phase 1
• Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated GlioblastomaCompletedNCT03452930Phase 1
• Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaWithdrawnNCT02599090Phase 2
• Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation TherapyTerminatedNCT01430351Phase 1
• Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or GliosarcomaTerminatedNCT00734526Phase 1
• Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with TemozolomideActive, not recruitingNCT00102648Phase 1